PROSTAGLANDINS, THE KIDNEY, AND HYPERTENSION
前列腺素、肾脏和高血压
基本信息
- 批准号:3336973
- 负责人:
- 金额:$ 30.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1977
- 资助国家:美国
- 起止时间:1977-09-01 至 1989-08-31
- 项目状态:已结题
- 来源:
- 关键词:adenylate cyclase adrenergic agents angiotensin II antihypertensive agents calcium gas chromatography glomerular filtration high performance liquid chromatography kidney circulation kidney metabolism kidney transplantation leukotrienes mass spectrometry nephrotic syndrome platelet activating factor prostaglandins radioimmunoassay renal glomerulus renal hypertension renal medulla salt intake thin layer chromatography thromboxanes tissue /cell culture vascular resistance vasopressins
项目摘要
We propose three major areas of investigation: 1) Glomerular and mesangial
cell contractility will be studied using a computer-based image analysis
microscopic system. We will assess the contractile effects of thromboxane
A2, leukotriene C4 and D4, and platelet activating factor on isolated rat
glomeruli and rat glomerular mesangial cells in culture. The glomerular
contractile actions of these compounds will be blocked with specific
antagonists to thromboxane receptors and leukotriene receptors. The
relaxant effect of PGE2 or PGI2 will be studied and the role of
intracellular cyclic AMP as the mediator of mesangial relaxation will be
evaluated. The importance of calcium entry or translocation of
intracellular calcium as a mediator of mesangial contraction in response to
the aforementioned contractile agents will also be studied; 2) Studies of
glomerular immune injury will use several models of nephrotoxic serum
nephritis induced by antiglomerular basement membrane antibodies.
Glomerular synthesis of leukotriene B4, C4 and D4 will be measured in
normal and immune-injured glomeruli. The actions of LTC4 and LTD4 on
glomerular function in vivo will be evaluated, after intrarenal infusion in
the rat, with measurements of glomerular filtration rate, renal blood flow
and urinary protein excretion. The therapeutic efficacy of lipoxygenase
inhibitors in nephrotoxic serum nephritis will be evaluated as will the
value of a leukotriene D4 receptor antagonist; 3) Renal medullary
prostaglandin synthesis will be measured in salt-sensitive, hypertensive
Dahl rats. Using cell culture techniques, we will determine whether
reduced PGE2 synthesis is in renal medullary interstitial cells or renal
papillary collecting tubular cells. Renal medullary interstitial cell
synthesis of anti-hypertensive polar renomedullary lipid (platelet
activating factor) will be measured and compared between hypertensive and
normotensive rats. Transepithelial salt transport will be assessed in
renal papillary collecting tubular cell monolayers and we will determine
whether this is the site of enhanced sodium reabsorption in hypertensive
salt-sensitive rats. The effects of prostaglandins and platelet activating
factor on renal papillary collecting tubular cell transport will be
measured.
我们提出了三个主要的研究领域:1)肾小球和系膜
将使用基于计算机的图像分析来研究细胞收缩性
微观系统 我们将评估血栓素的收缩作用
A2、白三烯C4和D4及血小板活化因子对离体大鼠的影响
培养的肾小球和大鼠肾小球系膜细胞。 肾小球
这些化合物的收缩作用将被特定的
血栓素受体和白三烯受体的拮抗剂。 的
将研究PGE 2或PGI 2的松弛作用,
作为系膜舒张介质的细胞内环AMP将被
评估。 钙进入或易位的重要性,
细胞内钙离子作为系膜收缩的介质
也将研究上述收缩剂; 2)研究
肾小球免疫损伤将使用几种模型的肾毒血清
抗肾小球基底膜抗体引起的肾炎。
将测量白细胞三烯B4、C4和D4的肾小球合成,
正常和免疫损伤的肾小球。 LTC 4和LTD 4对
将在肾内输注后评价体内肾小球功能,
测定大鼠肾小球滤过率、肾血流量
和尿蛋白排泄。 脂氧合酶的治疗效果
将评价肾毒性血清肾炎中的抑制剂,
白三烯D4受体拮抗剂的价值; 3)肾髓质
前列腺素的合成将在盐敏感性高血压患者中进行测量。
达尔老鼠。 利用细胞培养技术,我们将确定
减少的PGE 2合成是在肾髓质间质细胞或肾
乳头状集合管细胞。 肾髓质间质细胞
抗高血压肾髓质极性脂质(血小板)合成
激活因子)将被测量并比较高血压和
正常血压大鼠。 跨上皮盐转运将在
肾乳头集合管细胞单层,我们将确定
这是否是高血压患者钠重吸收增强的部位,
盐敏感的老鼠 灯盏花素与血小板活化作用
影响肾乳头集合管细胞转运的因素
测定了
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL J DUNN其他文献
MICHAEL J DUNN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL J DUNN', 18)}}的其他基金
VISION RES LAB: HERPETIC KERATIC, CORE PIGMENT GENES, RETINITIS PIGMENTOSA
VISION RES 实验室:疱疹性角化病、核心色素基因、色素性视网膜炎
- 批准号:
6794430 - 财政年份:2002
- 资助金额:
$ 30.26万 - 项目类别:
相似海外基金
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8358448 - 财政年份:2012
- 资助金额:
$ 30.26万 - 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8517552 - 财政年份:2012
- 资助金额:
$ 30.26万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7952159 - 财政年份:2009
- 资助金额:
$ 30.26万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7952152 - 财政年份:2009
- 资助金额:
$ 30.26万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7719194 - 财政年份:2008
- 资助金额:
$ 30.26万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7605416 - 财政年份:2007
- 资助金额:
$ 30.26万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7605425 - 财政年份:2007
- 资助金额:
$ 30.26万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7378753 - 财政年份:2006
- 资助金额:
$ 30.26万 - 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
- 批准号:
6825160 - 财政年份:2004
- 资助金额:
$ 30.26万 - 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
- 批准号:
2702283 - 财政年份:1997
- 资助金额:
$ 30.26万 - 项目类别: